2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Muscle Invasive Bladder Cancer: new trials by email Literature Review of Muscle Invasive Bladder Cancer trials Research Report on Muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 712 | 2021-08-05 | 2026-06-04 |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC Durvalumab, Cisplatin, Gemcitabine - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1063 | 2018-11-16 | 2026-10-15 |
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
durvalumab (2) · Cisplatin (1) · Cystectomy (1) · Gemcitabine (1) · enfortumab vedotin (1) · tremelimumab (1)
AstraZeneca (2)
Brazil (2) · Canada (2) · Chile (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2) · United Kingdom (2)
2018 (1), 2023 (1)